In American Psycho, Christian Bale’s character Patrick Bateman famously struggles to get a table at New York restaurant Dorsia. Hopefully brokers will be more accommodating to investors looking to get their hands on stock in Idorsia, which is to be spun out of Actelion (ALIOY) in the second quarter of 2017. Johnson & Johnson (JNJ) announced a deal… Read More »
Speculating about spinoffs – it’s not just for us, John Malone and deadline-driven journalists: 1) The Motley Fool handicaps the odds of a Johnson & Johnson (JNJ) spinoff in 2017. The basic premise is that JNJ has multiple segments with diverging sales trends (at least recently) so why not set one free. After playing through a few scenarios, the author ultimately suggests… Read More »
Supposedly addicts make great repeat customers, but unfortunately for Reckitt Benckiser (OTC:RBGLY), they (or at least insurers and pharmacies) are quite price sensitive. That seems to be one of the underlying reasons behind the consumer brand giant’s recent announcement of plans to spin off its pharmaceuticals business. The majority of the units’ $1.3b in revenues come from sales of… Read More »
What do you do when your drug discovery costs swamp your profits from a successful marketed drug. If you’re Elan Corporation(ELN), you spin off your drug discovery business with a bundle of cash, keeping your marketed drugs and late stage pipeline. Elan, an Irish biotech firm, is driven largely by Tysabri,a multiple sclerosis drug marketed with Biogen Idec(BIIB).… Read More »